|
Issue No.
13
| March 25, 2011
|
|
|
AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful. |
 |
|
 |
|
Study Reports High Rate of Selection for Lamivudine Mutations in HIV-Infected, Treatment-Naive Children at the Time of Virologic Failure
“We included all the human immunodeficiency virus (HIV) type 1-infected highly active antiretroviral therapy (HAART)-naive children who started an LPV/r-based regimen between 2000 and 2009 at the Necker Hospital (Paris, France). Virologic failure (VF) was defined as an HIV-RNA ≥50 copies/mL. Resistance genotypic test was performed in case of VF. …
“HAART included LPV/r and 2 nucleoside reverse-transcriptase inhibitors, mainly lamivudine (3TC), zidovudine, and/or abacavir. … Less than 50 copies/mL of HIV RNA was observed in 46%, 67%, and 70% of the children at months 6, 9, and 12, respectively. In all, 20 children (46.5%) experienced a VF. The risk factors of primary VF were a young age and a low socioeconomic status. The genotypic resistance test, performed for 18 of 20 children with VF, revealed 1 LPV/r-resistant virus and protease inhibitor-related major mutations without LPV/r resistance in 2 other children. Of the 18 children with VF, 15 received a 3TC-based HAART: 12 of 15 (80%) harbored a 3TC-resistant virus. No virus resistant to zidovudine or abacavir was found. …
“In all, 70% of HAART-naive children had virologic success at month 12. The selection of LPV-resistant strains was a rare event. A high rate of selection of 3TC-mutations strengthens the recommendation to prefer a first-line 3TC-sparing regimen, particularly for children with risk factors of poor adherence.”
More information is available:
AIDSinfo is now on Facebook!
AIDSinfo is pleased to expand its social media presence by releasing a Facebook page.
The AIDSinfo Facebook page is designed to keep you informed by posting:
- Announcements of newly released AIDSinfo content, such as revised HHS HIV treatment guidelines, HIV/AIDS awareness day specialty pages, and mobile applications
- Links to HIV/AIDS-related consumer fact sheets developed by AIDSinfo health information specialists based on information from the HIV treatment guidelines and other expert sources
- Breaking HIV/AIDS news and press releases on HIV/AIDS treatment and research
- Information from other government agencies involved in HIV/AIDS treatment and research
The page is also a great way to provide feedback on AIDSinfo resources.
Connect with AIDSinfo on Facebook.
|
|
|
|
|
|
